A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity

Purpose: Use of surrogate end point biomarkers in phase II trials may help select agents that appear to have activity and might be evaluated in future phase III definitive trials of breast cancer prevention. We performed a pilot clinical trial to establish the logistics for a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with novel imaging techniques and candidate surrogate end point biomarkers for activity. We chose tamoxifen to establish proof of principal with a known effective agent. Experimental Design: Women at a high risk of developing a new breast cancer and for whom tamoxifen was recommended were eligible. The women underwent baseline and 3 and 6 months mammogram and magnetic resonance imaging (MRI) of one breast to identify areas of water-like intensity (epithelial) and to determine the changes over time and MRI-directed core breast biopsies of these areas for surrogate end point biomarkers analysis. Results: From August 1999 to March 2001, 26 women underwent baseline imaging and core biopsies. Sixteen women took tamoxifen and 10 chose not to. Overall, 79% of the samples contained glandular tissue evaluable for histology, but only 66% of the samples were evaluable for marker analysis. Only 12 patients had specimens with glandular tissue sufficient for marker analysis both at baseline and in at least one follow-up. Because of the small number of women with matched samples, marker analysis was not informative. Conclusions: This study shows the feasibility of obtaining serial core breast biopsies from women at a high risk of developing a new breast cancer. Patient participation in this model is satisfactory, and such a model may provide indication of drug activity. MRI-directed biopsy did not provide a high yield of evaluable samples, and additional work on adequate collection of epithelial tissue for surrogate end point biomarker analysis is thus necessary.

[1]  Jon D. Miller,et al.  Public attitudes toward participation in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Paik,et al.  Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. , 2003, Journal of the National Cancer Institute.

[3]  R. J. Cersosimo.  Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.

[4]  William E Grizzle,et al.  A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[6]  M. Dowsett,et al.  Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[8]  Jianhua Xuan,et al.  MR-image-based tissue analysis and its clinical applications , 2002, SPIE Medical Imaging.

[9]  B. Ljung,et al.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. , 2001, Journal of the National Cancer Institute.

[10]  P. Sevelda,et al.  Lunar phases and survival of breast cancer patients – a statistical analysis of 3,757 cases , 2001, Breast Cancer Research and Treatment.

[11]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[12]  Christopher B Umbricht,et al.  Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR , 2001, The Lancet.

[13]  S. Manoir,et al.  Diagnosis of aneuploidy in archival, paraffin-embedded pregnancy-loss tissues by comparative genomic hybridization. , 2001, Fertility and sterility.

[14]  B. Fornage,et al.  Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[16]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[17]  M. Sporn,et al.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.

[18]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[19]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[20]  J. Cuzick,et al.  Drop-outs in tamoxifen prevention trials , 1999, The Lancet.

[21]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[22]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[23]  C. Osborne,et al.  bcl‐2 and apoptosis in lymph node positive breast carcinoma , 1998, Cancer.

[24]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  J. Pater.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[26]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[27]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[28]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[29]  R. Elledge,et al.  A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue , 2001 .

[30]  S. Kamel,et al.  Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials , 1997, Journal of cellular biochemistry. Supplement.

[31]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[32]  A. Stewart,et al.  Measuring Functioning and Well-Being: The Medical Outcomes Study Approach , 1992 .

[33]  R L Kane,et al.  Methodology for measuring health-state preferences--I: Measurement strategies. , 1989, Journal of clinical epidemiology.

[34]  C. Stratakis,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Comparative Genomic Hybridization Analysis of Adrenocortical Tumors of Childhood* , 2022 .